Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Jan 29, 2022 8:27am

234 Views

Post# 34374141

RE:Adlai Nortye

Yes that's interesting. I thought initial plan was to do study in parallel with phase 3 in North America/ Europe but it looks like that might not be the case. It's a new recent update to their website so they might be going ahead with it. It's a separate deal and they aren't subject to same FDA guidelines I'm guessing. There's definitely enough data to show that it's safe. So why not?

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing